New hope for rare HIV-2: drug combo shows promise
NCT ID NCT01605890
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a three-drug combination (raltegravir, emtricitabine, and tenofovir) as a first treatment for people with HIV-2, a less common form of HIV found mainly in West Africa. The goal was to see if this combination could control the virus better than standard treatments. Thirty participants who had never taken HIV drugs before were followed for 48 weeks to check if the treatment kept virus levels low and boosted immune cells.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV 2 INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hôpital Bichat-Claude Bernard
Paris, 75018, France